DelveInsight’s Autism Spectrum Disorders market report provide information on existing clinical strategies, new drugs, available therapies, epidemiology, Autism Spectrum Disorders market share of individual treatments, and current and forecasted Autism Spectrum Disorders market trends in the 7MM (the US, EU5 (the Uk, France, Germany, Italy, and Spain), and Japan.
Some of the Key Highlights from the Autism Spectrum Disorders Market Report
-
As per Centers for Disease Control and Prevention (CDC) estimate, approximately one in every 68 children in the United States has Autism.
-
According to Manabu Saito’s (2020) study in Japan, the adjusted Autism Spectrum Disorders prevalence was 3.22 percent.
-
Various pharmaceutical companies such as Curemark, Otsuka Pharmaceutical, Janssen Pharmaceutical, GW Research, Zynerba, Roche, and others are developing therapies to treat Autism Spectrum Disorders.
-
Key ASD pipeline therapies include CM-AT, Brexpiprazole, JNJ-42165279, GWP42006, Zygel, RO 7017773, and others.
-
RO 7017773 (Hoffmann-La Roche) is a small molecule that is a highly selective positive allosteric modulator of the GABAA 5 receptor, which is expressed in key brain regions for autism spectrum disorder.
-
GWP42006 (GW Research) is a non-psychoactive cannabinoid cannabidivarin (CBDV) extracted from the cannabis plant. The company has been testing GWP42006 in both general and syndromic pre-clinical models of ASD, with promising results on cognitive and social endpoints, as well as repetitive behavior.
For further information on the disease, request for the sample @ Autism Spectrum Disorders Market Analysis and Forecast
Autism Spectrum Disorders Overview
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by difficulties in social communication and interaction and restricted and repetitive patterns in behaviors, interests, and activities By definition, the symptoms appear early in development and interfere with daily functioning.
Autism Spectrum Disorders Epidemiology Segmentation
The Autism Spectrum Disorders report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
-
Autism Spectrum Disorders Total Prevalent Pool
-
Autism Spectrum Disorders Gender-Specific Prevalent Pool
-
Autism Spectrum Disorders Age-Specific Prevalent Pool
-
Autism Spectrum Disorders Total Diagnosed Cases
Autism Spectrum Disorders Therapeutics Market
There are numerous ASD treatment options available. The most effective ASD treatments used currently are Applied Behavioral Analysis (ABA), Occupational Therapy, Speech Therapy, Physical Therapy, and Pharmacological Therapy. Some FDA-approved drugs such as Risperidone, Aripiprazole, and Slenyto are also used to treat Autism Spectrum Disorders.
Autism Spectrum Disorders Market Outlook
The technological advancements achieved in the recent decade in terms of diagnosis, therapy, awareness, funding, and enhancing the functioning of a kid with ASD’s family provide hope for future ASD treatment.
Furthermore, the introduction of CM-AT, Brexpiprazole, JNJ-42165279, GWP42006, and others are expected to give the Autism Spectrum Disorders market a significant boost in the forecast period 2021-30 in the 7MM.
Get more information about the emerging treatment options @ Autism Spectrum Disorders Market Size
Autism Spectrum Disorders Pipeline Therapies and Key Companies
-
CM-AT: Curemark
-
Brexpiprazole: Otsuka Pharmaceutical
-
JNJ-42165279: Janssen Pharmaceutical
-
GWP42006: GW Research
-
Zygel: Zynerba
-
RO 7017773: Roche
Autism Spectrum Disorders Market Drivers
-
Increasing R&D
-
Rising ASD Prevalence
-
Government Initiatives
Autism Spectrum Disorders Market Barriers
-
Unknown etiology & pathophysiology
-
Lack of approved Therapies
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-30
Autism Spectrum Disorders Key Companies: Curemark, Otsuka Pharmaceutical, Janssen Pharmaceutical, GW Research, Zynerba, Roche, among others.
Autism Spectrum Disorders Key Pipeline Therapies: CM-AT, Brexpiprazole, JNJ-42165279, GWP42006, Zygel, RO 7017773, and others.
Autism Spectrum Disorders Segmentation: By Geography, By Autism Spectrum Disorders therapies
Analysis: Comparative and conjoint analysis of Autism Spectrum Disorders emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1. |
Report Introduction |
2. |
Autism Spectrum Disorders (ASD): Market Overview at a Glance |
3. |
Executive Summary |
4. |
Disease Background and Overview: Autism Spectrum Disorders (ASD) |
5. |
Epidemiology and Patient Population |
6. |
Assumptions and Rationale |
7. |
Autism Spectrum Disorders (ASD): Country-wise Epidemiology |
8. |
Organizations |
9. |
Patient Journey |
10. |
Case Report |
11. |
Autism Spectrum Disorders Marketed Products |
12. |
Autism Spectrum Disorders Emerging Therapies |
13. |
Key Cross Competitors |
14. |
Autism Spectrum Disorders (ASD): Market Size |
15. |
Autism Spectrum Disorders Unmet Needs |
16. |
Autism Spectrum Disorders Market Drivers |
17. |
Autism Spectrum Disorders Market Barriers |
18. |
KOL |
19. |
Report Methodology |
20. |
Sources Used |
21. |
DelveInsight Capabilities |
22. |
Disclaimer |
23. |
About DelveInsight |
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Related Reports
DelveInsight’s ‘Autism – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Autism epidemiology in the 7MM.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/